Search

Your search keyword '"Alho, Hannu"' showing total 539 results
Start Over Author "Alho, Hannu"
539 results on '"Alho, Hannu"'

25. Characteristics of Treatment Seeking Finnish Pathological Gamblers: Baseline Data from a Treatment Study

Author

Lahti, Tuuli, Halme, Jukka, Pankakoski, Maiju, Sinclair, David, and Alho, Hannu

Abstract

This article describes the socio-demographic characteristics and gambling behavior of 39 pathological gamblers who participated in our treatment study in 2009. The inclusion criteria of the study were: score of five or more on both the South Oaks Gambling Screen (SOGS) and a pathological gambling screen based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). The first 39 patients meeting the inclusion criterion were recruited into the study. The average age of the subjects was 39 years, and 80 % were males. The lag-time between active gambling (at least three times per week) and the onset of a pathological gambling problem was short: within 2 years of active gambling, 62 % of the subjects reported having become pathological gamblers. Our results also indicated certain gender-specific differences in the age at initiation and in the severity of the gambling problem. (Contains 4 tables and 2 figures.)

Published
2013
Full Text
View/download PDF

30. Rahapeliriippuvuuden varhainen tunnistaminen on tärkeää - uusia suuntaviivoja diagnostiikkaan, tukeen ja hoitoon

Author

Castrén, Sari, Raisamo, Susanna, Alho, Hannu, Kansanterveystieteen osasto, HUS Sisätaudit ja kuntoutus, Clinicum, and Hannu Eero Rafael Alho / tutkimusryhmä

Subjects
Behavior, Addictive, +therapy, +diagnosis, Gambling, 3142 Kansanterveystiede, ympäristö ja työterveys, Social Support, +rehabilitation
Abstract

Vertaisarvioitu. • Rahapeliriippuvuudella on yhtäläisyyksiä päihderiippuvuuksien kanssa. • ICD-11-tautiluokituksessa se on luokiteltu samaan luokkaan aine- riippuvuuksien kanssa. • Haittojen vähentämisessä auttavat varhainen tunnistaminen ja puheeksiotto. • Tukea ja hoitoa on saatavilla pääasiassa verkossa.

Published
2022

37. Alcohol dependence treatment in the EU: A literature search and expert consultation about the availability and use of guidelines in all EU countries plus Iceland, Norway, and Switzerland

Author

Rehm, Jürgen, primary, Rehm, Maximilien X., primary, Alho, Hannu, primary, Allamani, Allaman, primary, Aubin, Henri-Jean, primary, Bühringer, Gerhard, primary, Daeppen, Jean-Bernard, primary, Frick, Ulrich, primary, Gual, Antoni, primary, and Heather, Nick, primary

Published
2021
Full Text
View/download PDF

47. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe

Author

Marshall, Alison D., Cunningham, Evan B., Nielsen, Stine, Aghemo, Alessio, Alho, Hannu, Backmund, Markus, Bruggmann, Philip, Dalgard, Olav, Seguin-Devaux, Carole, Flisiak, Robert, Foster, Graham R., Gheorghe, Liana, Goldberg, David, Goulis, Ioannis, Hickman, Matthew, Hoffmann, Patrick, Jancorienė, Ligita, Jarcuska, Peter, Kåberg, Martin, Kostrikis, Leondios G., Makara, Mihály, Maimets, Matti, Marinho, Rui Tato, Matičič, Mojca, Norris, Suzanne, Ólafsson, Sigurður, Øvrehus, Anne, Pawlotsky, Jean-Michel, Pocock, James, Robaeys, Geert, Roncero, Carlos, Simonova, Marieta, Sperl, Jan, Tait, Michele, Tolmane, Ieva, Tomaselli, Stefan, van der Valk, Marc, Vince, Adriana, Dore, Gregory J., Lazarus, Jeffrey V., Grebely, Jason, International Network on Hepatitis in Substance Users (INHSU), Kostrikis, Leondios G. [0000-0002-5340-7109], Infectious diseases, AII - Infectious diseases, AII - Amsterdam institute for Infection and Immunity, APH - Digital Health, APH - Personalized Medicine, and APH - Global Health

Subjects
hepatitis C virus, HIV Infections, chemistry.chemical_compound, 0302 clinical medicine, Antiviral Agents/economics, HIV-HCV co-infection, 030212 general & internal medicine, Reimbursement, liver fibrosis, media_common, Dasabuvir, Coinfection, Health Policy, Gastroenterology, Hepatitis C, 3. Good health, Europe, Hepatitis C, Chronic/complications, Insurance, Health, Reimbursement, 030211 gastroenterology & hepatology, Switzerland, medicine.drug, medicine.medical_specialty, HIV Infections/complications, Antiviral Agents, Drug Costs, 03 medical and health sciences, hepatitis C treatment, medicine, Humans, media_common.cataloged_instance, European Union, European union, PWID, Intensive care medicine, Hepatitis, direct-acting antiviral, Hepatology, business.industry, Hepatitis C, Chronic, alcohol use, medicine.disease, reimbursement, Virology, Ombitasvir, chemistry, Paritaprevir, Ritonavir, business, treatment restrictions
Abstract

All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver. 3 2 125 133

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results